Advancing cellular therapies for blood cancers
Developments in Hodgkin lymphoma, CLL, multiple myeloma and follicular lymphoma
New salvage treatment for AML/MDS after allogeneic transplant: the VIOLA trial
The significance of FLT3 mutations in AML
Why do charities need to keep funding research into leukemia and blood cancer in general?